Status:
COMPLETED
Brain Exercise and Addiction Trial
Lead Sponsor:
Monash University
Collaborating Sponsors:
Turning Point
Conditions:
Cannabis Use Disorder, Moderate
Cannabis Use Disorder, Severe
Eligibility:
All Genders
20-55 years
Phase:
NA
Brief Summary
Heavy cannabis use is associated with substantive learning and memory impairments and elevated risk of psychopathology. It has been repeatedly demonstrated that the hippocampus, centrally implicated i...
Detailed Description
Heavy cannabis use is associated with substantive learning and memory impairments and elevated risk of psychopathology. It has been repeatedly demonstrated that the hippocampus, centrally implicated i...
Eligibility Criteria
Inclusion
- Aged 20-55 years
- Voluntary and able to provide informed consent
- Fluent in English
- Current moderate - severe cannabis use disorder
- Major history of cannabis use (i.e. ≥3 days per week on average for ≥4 of the past 6 years)
- Capacity to tolerate physical exercise according to 'Fitness to Exercise'
Exclusion
- Have a history of cardiovascular disease, high blood pressure, musculoskeletal injury or other condition that would preclude safe engagement in VO2 max fitness testing and/or regular physical exercise
- Severe claustrophobia, non-MR compatible metallic implant, or other contraindication to MRI scanning
- Lifetime history of significant neurological illness, or moderate - severe brain injury,
- Current major unstable medical illness or chronic pain condition
- Lifetime history of schizophrenia, schizoaffective disorder, OCD, PTSD, bipolar disorder
- Current significant depression or anxiety that precludes ability to reliably engage in the exercise program
- Current moderate - severe substance use disorder for substances other than cannabis (excluding nicotine)
- Currently pregnant or lactating
- Shift work employment schedule within the prior 6-months
- Have engaged in ≥5 sessions of HITT or resistance training within the past 12-months
- History of treatment with antipsychotic medications
- Current participation in psychosocial treatment for substance use disorder
- Other psychoactive medications or psychosocial treatments will be considered on a case-by-case basis. Where a current psychoactive medication is deemed acceptable, both dose and type must have been stable for a minimum of four weeks prior to baseline assessment, and remain stable throughout the 12-week exercise phase of the study.
Key Trial Info
Start Date :
January 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 21 2022
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04902092
Start Date
January 23 2019
End Date
November 21 2022
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Monash University, BrainPark
Melbourne, Victoria, Australia, 3800